New safety data on LYNPARZA for pancreatic cancer patients with BRCA mutation
NCT ID NCT04889404
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study looked at the safety of LYNPARZA (olaparib) when used as a maintenance treatment after platinum-based chemotherapy in 130 patients with BRCA-mutated pancreatic cancer that could not be surgically removed. Researchers tracked side effects like bone marrow problems, lung inflammation, new cancers, and harm to unborn babies. The goal was to understand real-world risks in this specific patient group.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Olaparib (LYNPARZA)
What this could lead to
If successful, this study could confirm that LYNPARZA is a safe maintenance option for people with BRCA-mutated pancreatic cancer after chemotherapy.
What could go wrong
This is an observational safety study, not a test of effectiveness. It may not show clear benefits, and side effects like bone marrow depression or lung issues remain possible.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PANCREATIC NEOPLASMS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Research Site
Osaka, Lyn010001, D081FC00004, Japan
-
Research Site
Kanagawa, Lyn010003, D081FC00004, Japan
-
Research Site
Okayama, Lyn010004, D081FC00004, Japan
-
Research Site
Akita, Lyn010005, D081FC00004, Japan
-
Research Site
Niigata, Lyn010006, D081FC00004, Japan
-
Research Site
Shizuoka, Lyn010007, D081FC00004, Japan
-
Research Site
Niigata, Lyn010008, D081FC00004, Japan
-
Research Site
Tokyo, Lyn010009, D081FC00004, Japan
-
Research Site
Saitama, Lyn010010, D081FC00004, Japan
-
Research Site
Aichi, Lyn010011, D081FC00004, Japan
-
Research Site
Osaka, Lyn010012, D081FC00004, Japan
-
Research Site
Tokyo, Lyn010013, D081FC00004, Japan
-
Research Site
Nara, Lyn010014, D081FC00004, Japan
-
Research Site
Wakayama, Lyn010015, D081FC00004, Japan
-
Research Site
Miyagi, Lyn010016, D081FC00004, Japan
-
Research Site
Tokyo, Lyn010017, D081FC00004, Japan
-
Research Site
Osaka, Lyn010018, D081FC00004, Japan
-
Research Site
Gunma, Lyn010019, D081FC00004, Japan
-
Research Site
Hiroshima, Lyn010020, Japan
-
Research Site
Tochigi, Lyn010021, D081FC00004, Japan
-
Research Site
Numakunai, Lyn010022, D081FC00004, Japan
-
Research Site
Osaka, Lyn010025, D081FC00004, Japan
-
Research Site
Shizuoka, Lyn010026, D081FC00004, Japan
-
Research Site
Nagasaki, Lyn010027, D081FC00004, Japan
-
Research Site
Kumamoto, Lyn010028, D081FC00004, Japan
-
Research Site
Saitama, Lyn010029, D081FC00004, Japan
-
Research Site
Nagano, Lyn010031, D081FC00004, Japan
-
Research Site
Hyōgo, Lyn010032, D081FC00004, Japan
-
Research Site
Shimane, Lyn010033, D081FC00004, Japan
-
Research Site
Hyōgo, Lyn010034, D081FC00004, Japan
-
Research Site
Shizuoka, Lyn010035, D081FC00004, Japan
-
Research Site
Hyōgo, Lyn010036, D081FC00004, Japan
-
Research Site
Okayama, Lyn010038, D081FC00004, Japan
-
Research Site
Fukuoka, Lyn010041, Japan
-
Research Site
Hokkaido, Lyn010042, Japan
-
Research Site
Ehime, Lyn010044, Japan
-
Research Site
Osaka, Lyn010045, Japan
-
Research Site
Shizuoka, Lyn010047, Japan
-
Research Site
Tokyo, Lyn010050, Japan
-
Research Site
Aichi, Japan
-
Research Site
Chiba, Japan
-
Research Site
Fukuoka, Japan
-
Research Site
Gunma, Japan
-
Research Site
Hiroshima, Japan
-
Research Site
Hokkaido, Japan
-
Research Site
Hyōgo, Japan
-
Research Site
Ibaraki, Japan
-
Research Site
Kagawa, Japan
-
Research Site
Kanagawa, Japan
-
Research Site
Kyoto, Japan
-
Research Site
Nagano, Japan
-
Research Site
Nagasaki, Japan
-
Research Site
Nara, Japan
-
Research Site
Okayama, Japan
-
Research Site
Osaka, Japan
-
Research Site
Shizuoka, Japan
-
Research Site
Tokyo, Japan
-
Research Site
Tottori, Japan
-
Research Site
Toyama, Japan
-
Research Site
Yamagata, Japan